NCT05159245View on ClinicalTrials.gov

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

November 25, 2026

Study Completion Date

November 25, 2026

Conditions
Advanced CancerSolid TumorHaematological Malignancy
Interventions
DRUG

Alectinib

ALK

DRUG

Cobimetinib

MEK1, MEK2

DRUG

Vismodegib

Hedgehog

DRUG

Trastuzumab+Pertuzumab

HER2

DRUG

Entrectinib

NTRK/ ROS1, ALK

DRUG

Atezolizumab

PD-L1

DRUG

Vemurafenib

BRAF V600

DRUG

Regorafenib

KIT/BRAF, RET

DRUG

Apalutamide

AR

DRUG

Abemaciclib

CDK4/6

DRUG

Tepotinib

MET ex14

DRUG

Dabrafenib

RAF

DRUG

Trametinib

MEK1, MEK2

DRUG

Dabrafenib+Trametinib

RAF, MEK1, MEK2

DRUG

Pemigatinib

FGFR2

Trial Locations (5)

Unknown

RECRUITING

Turku University Hospital Cancer Centre, Turku

RECRUITING

Kuopio University Hospital, Kuopio

RECRUITING

Oulu University Hospital OYS Cancer Center, Oulu

RECRUITING

Tampere University Hospital Department of Oncology, Tampere

00029

RECRUITING

Helsinki University Hospital Comprehensive Cancer Center, Helsinki

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER